Background {#Sec1}
==========

Breast cancer (BC) is the most prevalent type of cancer affecting females in both the developed and developing countries \[[@CR1]\]. Worldwide, it has been reported that about 1.4 million new cases are diagnosed annually with nearly close to10% of the newly diagnosed cases are women under the age of 40 \[[@CR2], [@CR3]\]. In Jordan, cancer is the second most common cause of death, preceded by cardiovascular diseases, with breast cancer being the most frequently occurring type of cancer among Jordanian females \[[@CR4]\]. Approximately, 15% of the newly diagnosed cases in Jordan are women under 40 years \[[@CR5]\].

The significant increased concern of breast cancer, worldwide and in Jordan, may be attributed to the prolonged life expectancy and the adoption of the western lifestyle with its related risk factors \[[@CR6]\]. Genetic mutations, alcohol consumption, obesity and physical inactivity were all related to increased breast cancer risk \[[@CR7], [@CR8]\].Interestingly, long-term utilization of oral contraceptives (OCs) has been associated with a small increase in breast cancer risk in young women \[[@CR9]\]. A 2013 meta-analysis estimated the lifetime absolute risk increment of breast cancer linked with ever versus never use of OCs at about 0.89% \[[@CR9]\]. The International Agency for Research on Cancer came to conclusion that there was enough evidence to support combined estrogen--progestin OCs carcinogenicity in humans, with an increased breast cancer risk limited to women who were currently utilizing or had recently utilized them \[[@CR10]\]. Data argue whether this risk is increased in women with family history of breast cancer \[[@CR11]\] or without influence of family history of breast cancer \[[@CR12]\].

Globally, around 140 million women worldwide utilize oral contraceptives; this portion approximately accounts for 13% of women between 15 and 49 years old \[[@CR13]\]. Among Jordanian women, intrauterine devices are the most preferred method of contraception followed by OCs \[[@CR14]\]. Unfortunately, there is scarcity of data exploring hormonal factors as intensifying risk for breast cancer in the Middle Eastern populaces, particularly in Jordan. For this reason, we performed an expanded case control study to examine the probability of such interaction, if exists, in the Jordanian female population.

Methods {#Sec2}
=======

Study participants {#Sec3}
------------------

Ethical approval to perform the study was obtained from the Scientific Committee at the King Hussein Cancer Center (IRB:17KHCC61). Participants' information remained confidential and within the institution. The study sample was selected via a non-random sampling method. All women who have been diagnosed with breast cancer (cases, *n* = 225) and who visited King Hussein Cancer Center breast cancer clinics between April and November 2017 were approached. Control cases were females, free of breast cancer that were matched for age to the study participants and they were selected conveniently from other clinics like ambulatory care, family medicine and gynecology. Entitled participants (cases and controls, *n* = 450) were women in the age category of 18 to 65 years old Jordanian females. Only participants who were able to provide an informed consent, based on a standard written statement, were eligible to fill the questionnaire and become part of the study. Information about history of breast cancer or any type of cancer, age at first child, and duration of breastfeeding, abortion, and age at menopause, smoking, and physical activity were all collected. In addition, participants were asked to provide detailed information regarding the use of OCs or any other hormonal replacement therapy. Demographic data were also obtained from all participants.

Data collection {#Sec4}
---------------

The questionnaire was structured based on initial discussions with health care professionals at the KHCC breast cancer clinics and careful inspection of literature \[Additional File [1](#MOESM1){ref-type="media"}\]. A group of four clinical pharmacists performed the interviews at the KHCC with the participating women confirming privacy and confidentiality of participants due to the sensitivity of the study population. All pharmacists were trained and instructed by the principle investigator (PI) to certify delivering the questionnaire in similar manner.

Statistical analysis {#Sec5}
--------------------

All data were coded, listed and analyzed using Statistical Package for Social Sciences program (SPSS®) database for Windows, version 23 (IBM, Chicago, IL). Kolmogorov Smirnov test was used to study the normal distribution of variables. The association between the incidence of physician diagnosed breast cancer and different factors was detected using Chi-square test. Mann Whitney-U test was used to assess the relation between time-dependent risk factor and breast cancer. Binary logistic regression was used to study the correlation between the incidence of breast cancer and possible risk factor, also to measure the degree of contribution of these risk factor to breast cancer. *P*-value \< 0.05 was used to indicate statistical significance.

Results {#Sec6}
=======

A total of 450 women, including women who have been diagnosed with breast cancer (cases, *n* = 225) and women who don't have breast cancer (controls, *n* = 225), were interviewed. Characteristics of the study population, demographics and descriptive properties of the sample, as education, the area of residence, occupation, income, marital status, and number of children, if any, are listed in Table [1](#Tab1){ref-type="table"}. Comparison data were represented by numbers and percentages. The vast majority of both cases and control samples were high school or higher educated (\> 70%), housewives (50% or more), and married (65% or more).Table 1Demographic and Characteristics of the Study Population (*N* = 450)Cases (*n* = 225)\
*N* (%)Controls (*n* = 225)\
*N* (%)Education (*N* = 449) Uneducated2 (0.8922 (9.44) Elementary22 (9.82)42 (18.03) High School42 (18.75)61 (26.18) College75 (33.48)56 (24.03) BSc^1^73 (32.59)44 (18.88) Postgraduate10 (4.46)8 (3.43)Residence (*N* = 448) Amman162 (72.65)75 (33.33) Other provinces61 (27.35)150 (66.67)Employment (*N* = 449) Employee/Job owner72 (32.14)78 (34.67) House Wife133 (59.38)112 (49.78) Retired19 (8.48)15 (6.67) Unemployed0 (0)20 (8.89)Monthly Income in JDs (*N* = 442)  \< 50077 (35.48)117 (52) 500--1000114 (52.53)99 (44)  \> 100026 (11.98)9 (4)Number of Dependents (*N* = 448)  ≤ 5155 (69.51)140 (62.22)  \> 568 (30.49)85 (37.78)Marital Status (*N* = 449) Single42 (18.7)36 (16) Married153 (68.3)173 (76.89) Divorced13 (5.8)4 (1.78) Widowed16 (7.14)12 (5.33)Parity (*N* = 450) Yes163 (72.44)173 (76.89) No62 (27.56)52 (23.11)Number of Children (*N* = 450) No56 (24.89)52 (23.11)  \< 480 (35.56)53 (23.56) 4--883 (36.89)113 (50.22)  \> 86 (2.67)7 (3.11)Chronic Diseases^a^ (*N* = 445) Hypertension25 (11.85)44 (22.11) Diabetes Mellitus3 (1.42)9 (4.52) Osteoporosis9 (4.27)1 (0.5) Morbid Obesity5 (2.37)0 (0) Blood Diseases1 (0.47)0 (0) Others6 (2.84)14 (7.04) None162 (76.78)131 (65.83)Thyroxin Therapy (*N* = 447) Yes24 (10.81)12 (5.330 No198 (89.19)213 (94.67)Tamoxifen Therapy (*N* = 446) Yes80 (36.04)0 (0) No142 (63.96)224 (100)Reasons of Oral Contraceptives Use (*N* = 446) Pregnancy Control62 (23.57)37 (16.59) Stop Period3 (1.14)8 (3.59) Others23 (8.75)3 (1.35) Nonuser175 (66.54)175 (78.48)Oral Contraceptives Prescriber (*N* = 136) Physician67 (76.14)44 (99.67) Nurse0 (0)1 (2.08) Pharmacist14 (15.91)3 (6.25) Others7 (7.95)0 (0)Getting MD^1^ Counseling (*N* = 27) Yes3 (13.04)0 (0) No20 (86.96)4 (100)^a^ more than one disease can be selected^1^*BSc* Bachelor of Science^1^*MD* Medical Doctor

As demonstrated in Table [2](#Tab2){ref-type="table"} and Table [3](#Tab3){ref-type="table"}, a comparison between cases and controls in term of risk factors revealed that no significant differences were detected between cases and controls with regard to age groups, breastfeeding and breastfeeding duration, history of miscarriage, regularity of period, previous use of hormonal therapy for menstrual cycle irregularities, the type of contraceptive pills, whether it was combined hormonal or only progesterone type, and age when the first child was born.Table 2Risk Factors in the Study Population, *p*-values from Chi-square test for Comparison between Cases and ControlsFactorCases (*n* = 224)\
*N* (%)Controls (n = 225)\
*N* (%)*p*-value^1^Age in years (*N* = 449) 18--3531 (13.84)31 (13.78)0.988 36--4589 (39.73)91 (40.44) 46--65104 (46.43)103 (45.78)Breastfeeding (*N* = 450) Yes144 (64)154 (68.44)0.522 No25 (11.11)19 (8.44) N/A^\*^56 (24.89)52 (23.11)Duration of breastfeeding in years (*N* = 449)  ≤ 150 (22.32)61 (27.11)0.610  \> 194 (41.96)93 (41.33) No24 (10.71)19 (8.44) N/A^\*^56 (25)52 (23.11)Pregnancy (*N* = 450) Yes115 (51.11)173 (76.89)0.000 No110 (48.89052 (23.11)Miscarriage (*N* = 450) Yes92 (40.89)84 (37.33)0.249 No133 (59.11)141 (62.67)Menopausal Status (*N* = 450) Premenopausal101 (44.89)74 (32.89)0.006 Postmenopausal124 (55.11)151 (67.11)Regularity of Period (*N* = 449) Yes190 (84.82)203 (90.22)0.056 No34 (15.18)22 (9.78)Personal history of cancer (ovarian, rectal, etc.) (N = 449) Yes27 (12.05)0 (0)0.000 No197 (87.95)225 (100)First or second -- degree relative have cancer (*N* = 449) Yes109 (48.66)34 (15.11)0.000 No115 (51.34)191 (84.89)Smoking Status (*N* = 448) Past Smoker25 (11.21)1 (0.44)0.000 Current Smoker11 (4.93)25 (11.11) Never Smoked187 (83.86)199 (88.44)Hormonal Therapy for Menstrual Irregularities (*N* = 447) Yes24 (10.81)13 (5.78)0.060 No198 (89.19)212 (94.22)Postmenopausal Hormonal Therapy (i = 448) Yes8 (3.59)0 (0)0.004 No215 (96.41)225 (100)Regular Use of Oral Contraceptives (*N* = 446) Yes87 (39.01)48 (21.52)0.000 No136 (60.99)175 (78.48)Oral Contraceptives Type (*N* = 81) COC^\*^31 (49.21)10 (55.56)0.063 POC^\*^32 (50.79)8 (44.44)^\*^*N/A* Not Applicable^\*^*POC* Progestin-Only Contraceptives^\*^*COCs* Combined Oral Contraceptives^1^Chi-square testTable 3Study Sample Characteristics in Two Groups, with Differences in Medians Expressed as Nonparametric t-test *p-values*ParameterGroupNMedian (IQR)*p*-value^c^Age at 1st childCases16922(20--26)0.765Control17323(20--25)Number of Miscarriage IncidencesCases1221(0.75--2.0)0.004Control851.3(1--2)Age at PubertyCases22213(12--14)0.000Control22514(13--15)Age at MenopauseCases10148(40.5--51)0.000Control7450(49--50)Duration of Oral Contraceptives Use^a^Cases2116.6 (4.2--9.1)^b^0.002Control2234.1 (2.4--5.8) ^ba^Duration recorded for the longest continuous use^b^Median (IQR)^c^Mann-Whitney Test

Nonetheless, significant differences were observed between cases and controls in terms of previous pregnancy (*p \< 0.001)*, menopausal status (*p \< 0.01)*, personal history of cancers other than breast cancer (*p \< 0.001)*, family history of cancer; first or second degree relatives (*p \< 0.001)*, smoking status (*p \< 0.001)*, use of hormonal replacement therapy (*p \< 0.01)*, number of previous miscarriages (*p \< 0.01)*, age at puberty and menopause (*p \< 0.001)*, and the use of OCs (*p \< 0.001)* as well as the duration of their use (*p \< 0.01)* (Table [2](#Tab2){ref-type="table"} and Table [3](#Tab3){ref-type="table"}). Additionally, OC users represent 39% of cases and 21.5% of controls (including both regular and intermittent use), while median use duration in months was 6.6 months for cases and 4.1 months for control.

Factors that have baseline significant difference between cases and controls were inserted into logistic regression utilizing stepwise method to test for significant association with the incidence of breast cancer (Table [4](#Tab4){ref-type="table"}). After adjustment for possible confounders, regular use of OCs showed association with incidence of breast cancer (OR~adjusted~ = 2.25, 95% CI 1.34--2.79; *p* = 0.002), while the duration of OCs use did show no association with the incidence of breast cancer (*p* \> 0.05). Other factors that demonstrated significant association with the incidence of breast cancer are listed in Table [4](#Tab4){ref-type="table"}. Interestingly, age at puberty, age at menopause, previous pregnancies, menopausal status, and family history of cancer were all among the factors that had significant relationship to breast cancer incidence.Table 4Tested Model Results Using Stepwise Logistic Regression AnalysisFactor^a^*p-value*OR (CI)Regular Use of Oral Contraceptive^b^0.0002.33 (1.54--3.55)Regular Use of Oral Contraceptive^c^0.0022.25 (1.34--2.79)Age at Puberty0.0050.23 (0.08--0.64)Age at Menopause0.0390.64 (0.42--0.98)Pregnancy (Yes-No)0.0000.21 (0.12--0.34)Menopausal Status (Premenopausal - Postmenopausal)0.0042.11 (1.27--3.49)First or second -- degree relative have cancer0.0004.07(2.42--6.83)^a^Only factors of significant effect in the tested model were shown^b^Unadjusted^c^Adjusted

Discussion {#Sec7}
==========

To our knowledge, this is the first case-control study to evaluate the link between the type and duration of contemporary oral contraceptives use and breast cancer risk in Jordanian women. The need for safe and effective contraception is a concern shared by women worldwide, including Jordanian women. While, OCs were viewed as convenient form of contraception \[[@CR14]\], there were concerns about their safety; 40.8% of Jordanian women thought that OCs are not safe, and 75.1% had experienced various side effects \[[@CR14]\].

A total of 5013 Jordanians and 2441 non-Jordanians residing in the Kingdom were diagnosed with cancer in 2012, according to the Health Ministry's annual statistics report for 2015 \[[@CR15]\] with about 2667 Jordanian women among those diagnosed, constituting 53.2%. Breast cancer is the most common form of cancer among Jordanian females, with 994 diagnoses in 2012 (37.3%), while lung cancer was the most common type of cancer among Jordanian males, with 282 cases diagnosed in the same year (12.4%) \[[@CR15]\]. There were few attempts to understand the risk factors of breast cancer in Jordanian women. A very recent hospital-based multi-center case-control study by Al-Qadiri et al (2018) \[[@CR16]\] has evaluated the risk factors of breast cancer in Jordanian women. Cases were older and had higher education than controls. Good lifestyle habits, such as exercising and eating healthy diet that focuses on fruits and vegetables, were associated with lower risk of breast cancer. Similar to our findings, Al-Qadiri et al found out that history of breast cancer in the first relatives is significantly associated with higher risk of breast cancer, but smoking, was not associated with breast cancer risk. However, the relationship between the use of OC use and BC risk was not assessed in Al-Qadir study. In a relatively less recent study in Jordan \[[@CR17]\], it was found that the use of fertility drugs, irregular periods, exposure to pesticides, chemicals and breast trauma were among the significant risk factors. Consistent with our findings, the earlier age of menarche and menopause and the use of hormonal therapy were associated with higher BC risk. Interestingly, the use of OCs was significantly associated with the risk of breast cancer (OR = 6.28, 95% CI: 3.14--12.55) \[[@CR17]\]. However, the link between the type and duration of contemporary OC use and BC risk in Jordanian women has not been investigated yet.

According to the results from the current study, women who used OCs regularly were at higher risk of developing breast cancer than their nonuser counterparts (OR~Adjusted~ = 2.25; 95% CI 1.34--2.79; *p* = 0.002), with no significant difference according to the type of OCs used, whether it was a combined oral contraceptive (COC) or progestin-only contraceptive (POC). Surprisingly, the risk was not increased with the duration of OCs use. Other risk factors include age at puberty, age at menopause, previous pregnancies, menopausal status, and family history of cancer.

Results from our study is consistent with previous ones. In 1996, a combined analysis encompassing about 90% of studies all over the world with 53,297 BC cases and 100,239 women without BC was published by the Collaborative Group on Hormonal Factors in Breast Cancer. It showed that there was a moderate increase in the relative risk of breast cancer of current COC users versus those who never used them. However, this risk diminishes proportionally with the number of years after last use, and then it disappears totally after 10 years of stopping the use \[[@CR12]\]. This relative risk was only slightly affected by identified risk factors of breast cancer such as age of menarche, menopause status and alcohol use. Comparably in our study, although these factors were significantly associated with OR of breast cancer, they had a small effect on OR of BC risk (2.33 vs. 2.25 of unadjusted vs. adjusted OR, respectively). Comparable to our finding, a statistically significant risk difference by oral contraceptive type or formulation was not found. Nevertheless, since the majority of the cases in the former study were diagnosed in the 1980s, it is expected that they use OC formulations that are different from the contemporary ones, even more, half of the studies were missing formulations data. A recent study, with smaller sample size "the Nurses' Health Study II", reported an increased in the risk of BC (RR = 1.3; 95% CI, 1.0--1.7) associated with current OCs use in general, especially with the use of one triphasic OCs (OR = 3.1; 95% CI, 2.0--4.7) \[[@CR18]\], after controlling for potential or know risk factors in their multivariate analysis, including but not limited to, age at menarche, family history of the cancer, menopausal status and current pregnancies, which were found to be significantly associated with the risk of BC in our study. Whereas the Women's Contraceptive and Reproductive Experiences (CARE) Study, found the BC risk was not associated with current use of OCs \[[@CR19]\] even when considering different types of OCs. But the (CARE) Study, in agreement with ours, found a significant different in cases and controls in age at menarche, menopausal status, number of pregnancies, use of hormonal therapy and family history. Recently, and based on pharmacy dispensing traces of women enrolled in a huge U.S. health plan, a study by Beaber et al evaluated the modern use of contemporary OC formulations used from 1989 to 2009 in the US. They reported that recent OCs use (within the last year) was associated with an increased BC risk (OR = 1.5; 95% CI, 1.3--1.9) relative to never or former OCs use. Contrasting our study, however, the use of contemporary OCs types, i.e. with low-dose estrogen, was not significantly associated with BC (OR = 1.0; 95% CI, 0.6--1.7). Nevertheless, the Beaber study had relatively short durations of continuous enrollment before reference date, so the exposure length to OCs could not be evaluated. Accordingly, the "never and former" OC users comprised the reference group, while in our analysis, the former users of OCs were included in the exposure group. In contrary to our study, where we collected data on potentially relevant confounders for all women, data on the possible confounders were unavailable for all women in the former study. Also, in Beaber et al study there were several analyses by OC type, and it is probable that some of the statistically significant findings they had may be due to chance as a result of the number of analyses performed.

Recently a very large-scale observational study from Denmark examined the association between the low-dose, more contemporary formulations of hormonal contraception \[[@CR20]\] including progestin-only contraceptives, and the risk for breast cancer in women younger than the age of 50. In concordance with our results, the study found that there is an increase in risk, yet small, (about a 20%), but in contrast to ours, the risk was proportional with duration of use. Also, this risk may persist after five years of cessation in women who used hormonal contraception for a minimum period of 5 years. The study by Mørch et al (2017) had much larger sample size than ours which allowed them to have sizable subgroups according to the type of OCs used. However, they did not adjust for potential factors with correlation to breast cancer such as age at menarche and breast-feeding or smoking status, which would have affected the calculated risk. Also, they lacked information about the exposure to OCs before study entry, but we have this type of information because the case-control type of study.

Limitations of our study include the retrospective type of research design which might have created a recall bias in some of the variables; for example, age of menarche, age of menopause and duration of OCs use. In addition, not all women in this study could self-report the type of OCs they have used and thus analysis based on the different combination doses was not possible. Those factors, along with the limited sample size and single-centered nature of study, make results of the current study ungeneralizable. However, the study focuses on the relationship between type and duration of OCs use and other risk factors with breast cancer in Jordanian women.

Conclusions {#Sec8}
===========

This study is the first report in Jordan to investigate the correlation between the contemporary and duration of use of OCs among Jordanian women and the risk of breast cancer. In addition to regular OCs use, significant differences in correlation of breast cancer were found between the case and the control groups, especially for the following risk factors: age at puberty, age at menopause, previous pregnancies, menopausal status, and family history of cancer. Future studies should include a larger sample size in multi-center setting all over the Kingdom. Also, the relationship between OCs use and specific subtypes of breast cancer \[Estrogen Receptor-Positive (ER^+)^, Estrogen Receptor-Negative (ER^-)^, Human Epidermal growth factor Receptor 2-Positive (HER2^+^), Progesterone Receptor-Positive (PR^+^)\] should be evaluated.

Findings from this study have implications in clinical practice. It is important for women to have this information before they decide to start using OCs. Healthcare providers should assist women in decision-making about alternative contraception methods such as intrauterine devices without hormone release, tubal ligation, and vasectomy for their partner. This decision needs to be made only after a careful discussion of benefits of contraception versus risks.

Additional file
===============

 {#Sec9}

Additional file 1:Questionnaire (PDF 204 kb)

BC

:   Breast Cancer

CARE

:   Contraceptive and Reproductive Experiences

COC

:   Combined Oral Contraceptive

ER^−^

:   Estrogen Receptor-Negative

ER^+^

:   Estrogen Receptor-Positive

HER2^+^

:   Human Epidermal growth factor Receptor 2-Positive

KHCC

:   King Hussein Cancer Center

OCs

:   Oral Contraceptives

PI

:   Principle Investigator

POC

:   Progestin-Only Contraceptive

PR^+^

:   Progesterone Receptor-Positive
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